SCHEMBL3326971

SCHEMBL3326971

C=CC(C)(C)Oc1ccc2oc3ccccc3c(=O)c2c1OC(C)(C)C=C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 9/20 0.47
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
PGAM1 P18669 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ABCG2 Q9UNQ0 2/20 0.41
SRD5A1 P18405 1/20 0.39
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133401 0.84 MAOA (0.57) MAOAKDM4EALDH1A1GLACYP3A4
SCHEMBL5612997 0.73 MAOA (0.69) MAOAKDM4EALDH1A1CYP3A4MAPT
SCHEMBL30255441 0.73 MAOA (0.69) MAOAKDM4EALDH1A1CYP3A4MAPT
SCHEMBL4452673 0.70 MAOA (0.50) MAOAKDM4EALDH1A1GLACYP3A4
SCHEMBL29833663 0.69 MAOA (0.52) MAOAKDM4EALDH1A1GLACYP3A4
SCHEMBL644478 0.69 MAOA (0.52) MAOAKDM4EALDH1A1GLACYP3A4
SCHEMBL4336089 0.67 CYP3A4 (0.53) MAOAKDM4EALDH1A1CYP3A4MAPT
SCHEMBL3326973 0.67 ALOX15 (0.50) MAOAKDM4EALDH1A1CYP3A4HPGD
SCHEMBL30435802 0.66 MAOA (0.68) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL8485668 0.65 MAOA (0.71) MAOAKDM4EALDH1A1CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2010-06-03 US disclosed
WO-2008057604-A9 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE UNIV CALIFORNIA (US) 2008-10-02 WO disclosed
WO-2008057604-A2 SMALL MOLECULE THERAPEUTICS, SYNTHESES OF ANALOGUES AND DERIVATIVES AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137421-A1 SMALL MOLECULE THERAPEUTICS, SYNTHESIS OF ANALOGUES AND DERIVATIVES AND METHODS OF USE BAD, CASP3, BID MAOA 3590/4885KDM4E 2993/4885ALDH1A1 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.